Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: A randomised controlled trial in healthy obese women

European Journal of Endocrinology

Volumn 180, Issue 6, 2019, Pages 417-427

  Otten, Julia ^a   Ryberg, Mats ^a   Mellberg, Caroline ^a   Andersson, Tomas ^a   Chorell, Elin ^a   Lindahl, Bernt ^a   Larsson, Christel ^b   Holst, Jens Juul ^c   Olsson, Tommy ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; FATTY ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY WEIGHT; BODY WEIGHT LOSS; CALORIC INTAKE; CALORIC RESTRICTION; CARBOHYDRATE INTAKE; CARBOXY TERMINAL SEQUENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DIET THERAPY; DIETARY COMPLIANCE; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT INTAKE; FAT MASS; FEMALE; GAS CHROMATOGRAPHY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MIDDLE AGED; NITROGEN URINE LEVEL; OBESE PATIENT; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PALEOLITHIC DIET; POSTMENOPAUSE; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; BLOOD; PHYSIOLOGY;

AGED; BIOMARKERS; DIET, PALEOLITHIC; ENERGY INTAKE; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MIDDLE AGED; OBESITY; POSTPRANDIAL PERIOD; WEIGHT LOSS;

EID: 85066329068     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-19-0082     Document Type: Article

References (37)

1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.Lancet 2012 380 2224-2260. (https://doi.org/10.1016/S0140-6736(12)61766-8)
2. Gogebakan O, Kohl A, Osterhoff MA, van Baak MA, Jebb SA, Papadaki A, Martinez JA, Handjieva-Darlenska T, Hlavaty P, Weickert MO et al. Effects of weight loss and long-term weight maintenance with diets varying in protein and glycemic index on cardiovascular risk factors: the diet, obesity, and genes (DiOGenes) study: a randomized, controlled trial. Circulation 2011 124 2829-2838. (https://doi.org/10.1161/CIRCULATIONAHA. 111. 033274)
3. Jonsson T, Granfeldt Y, Ahren B, Branell UC, Palsson G, Hansson A, Soderstrom M & Lindeberg S. Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study. Cardiovascular Diabetology 2009 8 35. (https://doi.org/10.1186/1475-2840-8-35)
4. Otten J, Stomby A, Waling M, Isaksson A, Tellstrom A, Lundin-Olsson L, Brage S, Ryberg M, Svensson M & Olsson T. Benefits of a Paleolithic diet with and without supervised exercise on fat mass, insulin sensitivity, and glycemic control: a randomized controlled trial in individuals with type 2 diabetes. Diabetes/Metabolism Research and Reviews 2017 33 e2828. (https://doi.org/10.1002/dmrr. 2828)
5. Manheimer EW, van Zuuren EJ, Fedorowicz Z & Pijl H. Paleolithic nutrition for metabolic syndrome: systematic review and meta-Analysis. American Journal of Clinical Nutrition 2015 102 922-932. (https://doi.org/10.3945/ajcn. 115. 113613)
6. Lindeberg S, Jonsson T, Granfeldt Y, Borgstrand E, Soffman J, Sjostrom K & Ahren B. A Palaeolithic diet improves glucose tolerance more than a Mediterranean-like diet in individuals with ischaemic heart disease. Diabetologia 2007 50 1795-1807. (https://doi.org/10.1007/s00125-007-0716-y)
7. Nauck MA, Bartels E, Orskov C, Ebert R & Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. Journal of Clinical Endocrinology and Metabolism 1993 76 912-917. (https://doi.org/10.1210/jcem. 76. 4. 8473405)
8. Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK & Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010 59 1765-1770. (https://doi.org/10.2337/db09-1414)
9. Flint A, Raben A, Astrup A & Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. Journal of Clinical Investigation 1998 101 515-520. (https://doi.org/10.1172/JCI990)
10. Færch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A, Pedersen O, Hansen T, Lauritzen T, Sandbæk A et al. GLP-1 response to oral glucose is reduced in prediabetes, screen-detected Type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study. Diabetes 2015 64 2513-2525. (https://doi.org/10.2337/db14-1751)
11. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R & Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996 38 916-919. (https://doi.org/10.1136/gut. 38. 6. 916)
12. Salera M, Giacomoni P, Pironi L, Cornia G, Capelli M, Marini A, Benfenati F, Miglioli M & Barbara L. Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity. Journal of Clinical Endocrinology and Metabolism 1982 55 329-336. (https://doi.org/10.1210/jcem-55-2-329)
13. Verdich C, Toubro S, Buemann B, Lysgard Madsen J, Juul Holst J & Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-effect of obesity and weight reduction. International Journal of Obesity and Related Metabolic Disorders 2001 25 1206-1214. (https://doi.org/10.1038/sj. ijo. 0801655)
14. Iepsen EW, Lundgren J, Holst JJ, Madsbad S & Torekov SS. Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36. European Journal of Endocrinology 2016 174 775-784. (https://doi.org/10.1530/EJE-15-1116)
15. Adam TC, Lejeune MP & Westerterp-Plantenga MS. Nutrient-stimulated glucagon-like peptide 1 release after body-weight loss and weight maintenance in human subjects. British Journal of Nutrition 2006 95 160-167. (https://doi.org/10.1079/BJN20051614)
16. Felig P. Amino acid metabolism in man. Annual Review of Biochemistry 1975 44 933-955. (https://doi.org/10.1146/annurev. bi. 44. 070175. 004441)
17. Borghi VC, Wajchenberg BL & Cesar FP. Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance. Metabolism: Clinical and Experimental 1984 33 1068-1074. (https://doi.org/10.1016/0026-0495(84)90089-1)
18. Mellberg C, Sandberg S, Ryberg M, Eriksson M, Brage S, Larsson C, Olsson T & Lindahl B. Long-term effects of a Palaeolithic-type diet in obese postmenopausal women: a 2-year randomized trial. European Journal of Clinical Nutrition 2014 68 350-357. (https://doi.org/10.1038/ejcn. 2013. 290)
19. Alexander J, Anderssen SA, Aro A, Becker W, Fogelholm M, Lyhne N, Meltzer HM, Pedersen AN, Pedersen JI & órsdóttir I. Nordic Nutrition Recommendations 2004, Integrating Nutrition and Physical Activity, 4th ed. Copenhagen: Norden, 2004.
20. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK & Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism 2001 86 3717-3723. (https://doi.org/10.1210/jcem. 86. 8. 7750)
21. Reaven GM, Chen YD, Golay A, Swislocki AL & Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 1987 64 106-110.(https://doi.org/10.1210/jcem-64-1-106)
22. Knop FK, Vilsboll T, Madsbad S, Holst JJ & Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i. v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007 50 797-805. (https://doi.org/10.1007/s00125-006-0566-z)
23. Orskov C, Rabenhoj L, Wettergren A, Kofod H & Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994 43 535-539.
24. Lindgren O, Carr RD, Deacon CF, Holst JJ, Pacini G, Mari A & Ahren B. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. Journal of Clinical Endocrinology and Metabolism 2011 96 2519-2524. (https://doi.org/10.1210/jc. 2011-0266)
25. Møller CL, Vistisen D, Færch K, Johansen NB, Witte DR, Jonsson A, Pedersen O, Hansen T, Lauritzen T, Jørgensen ME et al. Glucose-dependent insulinotropic polypeptide is associated With lower low-density lipoprotein but unhealthy fat distribution, independent of insulin: the ADDITION-PRO study. Journal of Clinical Endocrinology and Metabolism 2016 101 485-493. (https://doi.org/10.1210/jc. 2015-3133)
26. A J, Trygg J, Gullberg J, Johansson AI, Jonsson P, Antti H, Marklund SL & Moritz TExtraction and GC/MS analysis of the human blood plasma metabolome. Analytical Chemistry 2005 77 8086-8094. (https://doi.org/10.1021/ac051211v)
27. Otten J, Mellberg C, Ryberg M, Sandberg S, Kullberg J, Lindahl B, Larsson C, Hauksson J & Olsson T. Strong and persistent effect on liver fat with a Paleolithic diet during a two-year intervention. International Journal of Obesity 2016 40 747-753. (https://doi.org/10.1038/ijo. 2016. 4)
28. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A & Proietto J. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine 2011 365 1597-1604. (https://doi.org/10.1056/NEJMoa1105816)
29. Adam TC, Jocken J & Westerterp-Plantenga MS. Decreased glucagon-like peptide 1 release after weight loss in overweight/obese subjects. Obesity Research 2005 13 710-716. (https://doi.org/10.1038/oby. 2005. 80)
30. Svendsen PF, Jensen FK, Holst JJ, Haugaard SB, Nilas L & Madsbad S. The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women. Scandinavian Journal of Clinical and Laboratory Investigation 2012 72 410-419. (https://doi.org/10.3109/00365513. 2012. 691542)
31. Holst JJ & Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005 48 612-615. (https://doi.org/10.1007/s00125-005-1705-7)
32. Ranganath L, Norris F, Morgan L, Wright J & Marks V. The effect of circulating non-esterified fatty acids on the entero-insular axis. European Journal of Clinical Investigation 1999 29 27-32. (https://doi.org/10.1046/j. 1365-2362. 1999. 00426. x)
33. Bailey CJ, Flatt PR, Kwasowski P, Powell CJ & Marks V. Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. Acta Endocrinologica 1986 112 224-229. (https://doi.org/10.1530/acta. 0. 1120224)
34. Sloth B, Due A, Larsen TM, Holst JJ, Heding A & Astrup A. The effect of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite and glucose metabolism during a 6-month weight maintenance period. British Journal of Nutrition 2009 101 1846-1858. (https://doi.org/10.1017/S0007114508137710)
35. Filippi BM, Abraham MA, Yue JT & Lam TK. Insulin and glucagon signaling in the central nervous system. Reviews in Endocrine and Metabolic Disorders 2013 14 365-375. (https://doi.org/10.1007/s11154-013-9258-4)
36. Cegla J, Troke RC, Jones B, Tharakan G, Kenkre J, McCullough KA, Lim CT, Parvizi N, Hussein M, Chambers ES et al. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 2014 63 3711-3720. (https://doi.org/10.2337/db14-0242)
37. Wewer Albrechtsen NJ, Bak MJ, Hartmann B, Christensen LW, Kuhre RE, Deacon CF & Holst JJ. Stability of glucagon-like peptide 1 and glucagon in human plasma. Endocrine Connections 2015 4 50-57. (https://doi.org/10.1530/EC-14-0126)